Protozoan Infections
12
0
2
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (12)
Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria
A Study to Compare Two Dosing Regimens for a New Malaria Vaccine
Egg Intervention During Pregnancy in Indonesia
Possible Association of Intestinal Helminths and Protozoa With Colorectal Cancer Pathogenesis
Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis
Parasitism & COVID19 Vaccines: New Challenge.
Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158
Chagas Disease Diagnostic - Inconclusive Serology
Intestinal Protozoal Infections and Sexual Transmitted Diseases Among Targeted Cohorts
A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis